StonkScan
OverviewRevenueFinancialsValuationOutlookOwnership
Price
Performance · vs S&P 500
Company
Intuitive Surgical, Inc.
NASDAQ · USD
Large cap
In line with peers
2.89× peer median
46% more volatile
Claude reads this page's data and writes up Intuitive Surgical, Inc.'s financials, valuation and analyst coverage: built only from the figures here, with nothing pulled in from elsewhere.
Generated by an AI model from the data on this page. It can be wrong, and it isn't investment advice or a recommendation to buy or sell anything. Check every figure against the sections themselves before you rely on it.
31.9% in FY21 to 29.3% in FY25.
Profitability · FY25
$5.7B in FY21 to $10.1B in FY25, with the latest year up 20.5%.
Growth · FY25
$7.2B of free cash flow against $10.0B of net income across 5 fiscal years.
Quality · FY25
Free cash flow of $2.5B covers the business without outside capital, on $5.9B of cash and short-term investments.
Liquidity · FY25
$5.9B of cash and short-term investments against $171M of total debt.
Liquidity · FY25
$9.8B of current assets against $2.0B due within a year.
Liquidity · FY25
$10.1B of revenue against $7.1B of operating costs, leaving $2.9B.
Profitability · FY25
Revenue came in above consensus by 4.0% on average over the last four reports.
Quality · Jul '26
Tech giant Nvidia has remained ahead of rivals thanks to its competitive advantage. These healthcare companies have proven expertise in their fields -- and they would be difficult to unseat.
Intuitive Surgical dominates the robotic surgery market, and this has led to earnings growth over time. Some investors have worried about a slowdown in U.S. procedure growth in recent times.
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
In the most recent trading session, Intuitive Surgical, Inc. (ISRG) closed at $372.6, indicating a +1.51% shift from the previous trading day.
ISRG's record cash flow is fueling R&D, manufacturing expansion and over 100 da Vinci 5 updates, strengthening its innovation edge.
Intuitive Surgical leads surgical robotics with faster procedure growth and recurring revenue, while Medtronic offers a cheaper, diversified growth profile.
Average month-end to month-end move for ISRGin each calendar month. Point at a bar for that month's spread: past seasonality is a tendency in a small sample, not a forecast.
+$1.7B vs FY24
FY24 → FY25
FY21 → FY25, annualized
+20.7% vs the four before
Q2 FY26 · +18.5% YoY
Share of the latest fiscal year, largest first. The line is the segment across every fiscal year we have: hover it to read one.
No filing with a machine-readable geographic breakdown for ISRG yet.
+20.5% YoY
−1.5 pp YoY
+1.2 pp YoY
+23.0% YoY
+0.6 pp YoY
+22.3% YoY
+91.0% YoY
+44.8% YoY
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Cash & equivalents | 3.4 | 2.0 | 2.8 | 1.6 | 1.3 |
| Short-term investments | 2.6 | 2.0 | 2.5 | 2.5 | 2.9 |
| Receivables | 1.6 | 1.4 | 1.3 | 1.1 | 0.9 |
| $ billions | FY25 | FY24 | FY23 | FY22 | FY21 |
|---|---|---|---|---|---|
| Operating cash flow | 3.0 | 2.4 | 1.8 | 1.5 | 2.1 |
| Capital expenditure | −0.5 | −1.1 | −1.1 | −0.5 | −0.4 |
| Free cash flow | 2.5 | 1.3 | 0.7 |
P/E vs EPS growth · below the channel = cheaper for its growth
P/S vs revenue growth · below the channel = cheaper for its growth
| Ticker | P/E | Fwd P/E | PEG | P/S | Fwd P/S | PSG | EPS gr | Rev gr |
|---|---|---|---|---|---|---|---|---|
| ISRG | 41.8 | 34.2 | 1.76 | 11.8 | 11.1 | 0.78 | 19% | 14% |
| BDX | 56.5 | 14.8 | 0.43 | 2.5 | 2.7 | - | 34% | -2% |
| RMD | 22.0 | 18.9 | 1.63 | 5.9 | 5.7 | 1.10 | 12% | 5% |
| WST | 43.5 | 38.2 | 2.06 | 7.3 | 7.1 | 0.92 | 19% | 8% |
| HOLX | 31.3 | 17.2 | 0.63 | 4.1 | 4.0 | 1.03 | 27% | 4% |
| COO | 59.9 | 15.3 | 0.36 | 3.3 | 3.2 | 0.63 | 42% | 5% |
Dots = reported EPS vs consensus · gap = surprise · dashed = estimate ($)
Solid = reported · dashed = forward consensus · shaded = analyst low–high ($B)
Rows: discount rate (r) · Columns: terminal growth (g∞) · cell = fair value, shaded by up/downside vs 370.
Last 12M · $0M bought · $21M sold · net −$21M
| Inventory |
|---|
| 1.8 |
| 1.5 |
| 1.2 |
| 0.9 |
| 0.6 |
| Total current assets | 9.8 | 7.1 | 7.9 | 6.3 | 5.8 |
|---|
| Property, plant & equipment | 5.3 | 4.8 | 3.5 | 2.4 | 1.9 |
|---|
| Long-term investments | 3.3 | 5.1 | 2.1 | 2.6 | 4.4 |
|---|
| Other non-current assets | 2.2 | 1.9 | 1.9 | 1.7 | 1.4 |
|---|
| Total assets | 20.6 | 18.8 | 15.4 | 13.0 | 13.6 |
|---|
| Accounts payable | 0.3 | 0.2 | 0.2 | 0.1 | 0.1 |
|---|
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
|---|
| Total current liabilities | 2.0 | 1.7 | 1.7 | 1.4 | 1.1 |
|---|
| Long-term debt | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
|---|
| Total liabilities | 2.7 | 2.3 | 2.0 | 1.9 | 1.6 |
|---|
| Shareholders’ equity | 17.8 | 16.4 | 13.3 | 11.0 | 12.0 |
|---|
Fiscal year · latest five reported years
| 1.0 |
| 1.7 |
| Investing cash flow | 0.7 | −3.3 | −0.4 | 1.4 | −2.5 |
|---|
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
|---|
| Share buybacks | −2.3 | 0.0 | −0.4 | −2.6 | 0.0 |
|---|
| Net debt issued / (repaid) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
|---|
| Financing cash flow | −2.4 | 0.2 | −0.3 | −2.6 | 0.0 |
|---|
| Net change in cash | 1.3 | −0.7 | 1.2 | 0.3 | −0.3 |
|---|
Fiscal year · outflows shown negative